Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × Tiragolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumors 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 PD-L1-selected Solid Tumors 1 Neoplasms 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Renal Cell 1 Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Advanced Rare Malignant Solid Neoplasm 1

Interventions

Cisplatin 56 Paclitaxel 25 Radiotherapy 24 Carboplatin 21 Bevacizumab 20 pembrolizumab 18 Brachytherapy 15 atezolizumab 9 Gemcitabine 9 camrelizumab 8 Topotecan 8 Nivolumab 8 Radiation 7 zimberelimab 6 tislelizumab 6 Docetaxel 6 Albumin-Bound Paclitaxel 6 toripalimab 5 nimotuzumab 5 lenvatinib 5 dostarlimab 5 Taxes 5 Papillomavirus Vaccines 5 Drug Therapy 5 Chemoradiotherapy 5 Cetuximab 5 durvalumab 4 Platinum 4 Magnetic Resonance Spectroscopy 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04300647 2026-03-12

SKYSCRAPER-04

Hoffmann-La Roche

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡